This is part of an EAP, so I'm not too sure what you were expecting.
Of course the data is not complete and hence a trial is required.
But, it has gone beyond talk and heresay, it's been published for public scrutiny - that's an important step
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-58
-
- There are more pages in this discussion • 366 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.008(0.64%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $1.748M | 1.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 61024 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 11519 | 6 |
View Market Depth
| Last trade - 12.00pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |